---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031643"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:51:07.717441+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q1 net loss $14.8M; Phase 1 SL-325 enrollment complete, data Q2 2026

## Summary
- Cash and equivalents $90.4M as of March 31, 2026, up from $60.9M a year ago; cash runway into 2029 assuming warrant exercise.
- Phase 1 trial of SL-325 (DR3 blocking antibody) enrollment complete; safety, PK, PD data expected Q2 2026.
- Phase 2 trial in Crohn's disease expected to initiate Q3 2026, subject to positive Phase 1 data and regulatory alignment.
- Net loss $14.8M ($0.13 per share) vs $13.7M ($0.27) in Q1 2025; R&D expenses $10.9M vs $9.9M.
- Lead bispecific DR3 antibody in IND-enabling activities; target disclosure and preclinical data expected Q2 2026.

## SEC filing metadata
- accession: 0001628280-26-031643
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000162828026031643/0001628280-26-031643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000162828026031643/sttk-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031643
- JSON: https://secwatch.observer/filing/0001628280-26-031643.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031643.txt

## Source-grounded claims
- claim_id: af6b0132c68c980f51b2234af386563baff617e6
  claim: Shattuck Labs, Inc. reported first quarter ended March 31, 2026 results: net income $14.8 million for the quarter ended March 31, 2026, or $0.13 per basic and diluted share, EPS $0.13 per basic and diluted share.
  evidence_excerpt: Shattuck Labs Reports First Quarter 2026 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680367/000162828026031643/0001628280-26-031643-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.